West Pharmaceutical Services (WST) Revenue (2009 - 2026)

West Pharmaceutical Services (WST) has reported Revenue for 18 consecutive years, with $872.3 million the latest figure, recorded in Q2 2026.

• Quarterly Revenue rose 13.8% year-over-year to $872.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 12.38% YoY) and the FY2025 annual result came in at $3.1 billion, up 6.25% from the prior year.
• Revenue grew to $872.3 million in Q2 2026 per WST's latest filing, from $844.9 million in the prior quarter.
• Over the last five years, Revenue for WST reached as high as $872.3 million in Q2 2026 and fell as low as $686.9 million in Q3 2022.
• A 5-year average of $751.2 million and a median of $747.2 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue fell 6.86% — and 2026, when it climbed 21.05%.
• Year by year, Revenue stood at $708.7 million in 2022, then advanced by 3.29% to $732.0 million in 2023, then increased by 2.3% to $748.8 million in 2024, then grew by 7.51% to $805.0 million in 2025, then climbed by 8.36% to $872.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $872.3 million, $844.9 million, and $805.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.